Peptide safety
"Is this safe?" is the right first question. These articles look at peptide safety — what data actually exists for peptides and GLP-1 medications: what trials measured, what has only been studied in animals, how sourcing and compounding affect quality, and which red flags matter when you read claims online.
The prescription requirement exists precisely for this: a licensed provider weighs your health history before anything ships — and can say no. The same standard applies across the site: what a study measured, in whom, and for how long.
123 articles on this topic
-
Is Sermorelin FDA Approved? Not Since 2009
Geref, the only sermorelin product the United States ever approved, left the market in 2008 and its approvals were withdrawn in 2009 — not over safety. Here is what that means for a prescription today.
-
Kisspeptin for Men: What the Studies Really Show
Kisspeptin may affect reproductive hormones and sexual response in men. The evidence is promising but small, and it does not establish a standard dose or long-term treatment plan.
-
Semaglutide and Heart Health: What Studies Show
Semaglutide has been linked to fewer major cardiovascular events in a specific high-risk group, and to better symptoms in one type of heart failure. The numbers are meaningful, but they do not apply to every heart or every formulation.
-
Semaglutide and Vision: What's Real, What's Rare
Most people never have an eye problem because of semaglutide. Two things do come up, though, and they get mixed together constantly — so here is what each one actually is.
-
Semaglutide for Heart Failure Now Has ESC Support
Europe's 2026 heart-failure guideline now says semaglutide or tirzepatide should be considered for symptomatic patients with obesity and an ejection fraction of at least 45%. The recommendation is about symptoms, walking capacity, and quality of life—not proof that semaglutide prevents death.
-
Tirzepatide Diabetic Retinopathy: Who It's For
The tirzepatide diabetic retinopathy warning landed on both U.S. labels in August 2026. It asks for eye monitoring in people who already have the condition — not a finding that the medicine harms eyes.
-
Tirzepatide Heart Benefits: Who the Label Covers
In August 2026 the brand-name version of tirzepatide gained a new use on its label: lowering the risk of heart attack, stroke and cardiac death in adults with type 2 diabetes. Here is what that covers, and what it doesn't.
-
CJC-1295 Ipamorelin for Women: Evidence and Limits
CJC-1295 with ipamorelin may stimulate the growth-hormone axis, but no clinical trial has tested the combination specifically in women. Perimenopause, estrogen route and the limits of body-composition and sleep evidence all matter to the prescribing decision.
-
Does CJC-1295 Ipamorelin Work? Evidence Review
The combination has no clinical trial of its own. Separate studies show that CJC-1295 and ipamorelin can raise growth hormone signals, but they do not establish predictable sleep, recovery, muscle, or fat-loss results from the blend.
-
Does Sermorelin Cause Hair Loss? Evidence Review
Current evidence does not identify hair loss as a sermorelin side effect. Growth hormone and IGF-1 affect follicles, but that biology cannot explain why one person starts shedding.
-
GLP-1 Patches: Do They Work?
GLP-1 patches sold online are usually supplement stickers, not semaglutide or tirzepatide. Ordinary patches cannot move these large peptide drugs across intact skin in a predictable dose.
-
Kisspeptin Side Effects: What Human Trials Found
Short human trials suggest few systemic effects, while injection-site stinging can happen and repeated exposure can blunt the hormone response. The major unknown is long-term safety.
-
Semaglutide and Aging: The New Study Is in Mice
A new Nature study found longer life and better physical function in old female mice given semaglutide. It did not test people, so it cannot tell us that semaglutide slows human aging or adds years to human life.
-
Semax for ADHD: What the Evidence Actually Shows
Semax has not been tested in a human ADHD trial. The attention claims come from a small study in healthy volunteers, neurological research, and a biological hypothesis—not evidence that it treats ADHD.
-
Tesamorelin for Women: Evidence and Menopause
Tesamorelin for women has limited female-specific evidence: pivotal trials enrolled 84%–86% men, and no trial was designed for menopause-related abdominal change. Hormone therapy, pregnancy, glucose and IGF-1 all change the prescribing conversation.
-
Tesamorelin Injections: Sites, Timing, and Storage
Tesamorelin is injected under the skin once daily. The abdomen, site rotation, timing, device format, and storage instructions all matter—and they are not identical across branded and compounded formulations.
-
What Is Semax Used For? Evidence and Status
Semax is used in Russia for defined neurological and optic-nerve indications. In the United States, interest centers on focus and memory, but the human evidence for those nootropic uses is small and indirect.
-
The FDA Peptide Decision Hasn't Been Made Yet
An FDA advisory panel voted on seven peptides in July. Weeks on, nothing has been published — and that gap is the whole story.
-
FDA Peptide Warning Letters: What They Mean
FDA’s five August 24 letters targeted the way online sellers presented injectable peptides for people—not peptide molecules as a class. Here’s what changed, what didn’t, and how a prescription route differs.
-
BPC-157 Arginate vs Acetate: What Changes?
Arginate and acetate name salt forms of the same 15-amino-acid peptide. The counter-ion may change formulation properties, but no published in-vivo comparison shows that one produces better clinical outcomes.
Page 1 of 7 · 123 articles